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which they termed “the coronary collier.” Although this single
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July 20, 2010:317–202Y12 inhibitors or to the setting of long-term therapy is
nclear and requires further study.
Although limitations of this analysis, including a single-time
oint assessment of platelet function, the lack of a uniformly
ccepted bleeding definition, and its observational design, need to
e recognized, we do think that the present analysis supports the
ypothesis that the association of P2Y12 receptor inhibition and
schemic events is characterized by a threshold phenomenon and
hat a therapeutic window of P2Y12 receptor inhibition does exist,
ith patients within this range exhibiting low risk for both
leeding and ST.
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aliwango et al. (1) recently provided a beautiful coronary com-
uted tomographic angiographic illustration of a rare anomaly,oronary artery variant (arising from the right coronary cusp and
oursing the entire atrioventricular groove before terminating in
he anterior interventricular sulcus) is certainly uncommon, it is
ot “new” to the literature. This coronary artery anomaly was
reviously identified on the post-mortem examination of the lateFigure 1 Adverse Events and Levels of P2Y12 Receptor Inhibition
(A) Thirty-day incidence of definite or probable stent thrombosis (ST) (black
line) and incidence of in-hospital major bleeding events (red line). Patients are
stratified into groups of enhanced responders (area under the aggregation
curve [AUC] 188), normal responders (AUC 189 to 467), and low responders
(AUC 468). (B) Incidence of adverse events (combined for ST and major
bleeding) across responder groups. p values reported were calculated across
all 3 groups using chi-square tests.asketball star Pete Maravich (2). Histology revealed patchy
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July 20, 2010:317–20carring and interstitial fibrosis in the subendocardial regions of the
nterior and apical left ventricle, without significant cellular
nfiltrate. The pathologic findings were thought to be consistent
ith chronic ischemia in the distribution of the terminal circula-
ion (left anterior descending artery territory). The authors of this
arlier paper concluded that this portion of the heart had a
ombined ischemic blood supply coupled with an excessive de-
and on the limited circulation. Perhaps a similar pathophysiology
ontributed to the chest pain symptoms reported in their 59-year-
ld female patient.
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eply
e thank Dr. Symanski for his interest in our article describing a
are coronary anomaly (1). We are grateful that he brings to our
ttention the post-mortem results of Pete Maravich’s heart (2). We
gree that this anomaly, unbeknownst to us, has been previously
escribed.
It was interesting to read the post-mortem examination that
escribed a dilated heart weighing 650 g and having a left
entricular wall thickness of 15 mm. Equally interesting were the
ndings of myocardial fibrosis consistent with chronic ischemia.
r. Symanski questions whether a similar pathophysiology may be
ontributing to our patient’s chest pain.
At follow-up, our patient’s atypical chest pain had completely
esolved. On further review, our patient also had normal left
entricular volumes, mass, and ejection fraction. Cocker et al.
3) recently described the finding of myocardial fibrosis in elite
thletes using magnetic resonance imaging. We wonder
hether Pete Maravich’s history as an elite athlete in combi-
ation with this rare coronary anomaly partially explains his
ost-mortem findings.
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ertebral Artery Stenting
ot Quite Ready for Prime Time!
therosclerotic vertebral artery (VA) stenosis is a significant cause
f vertebrobasilar ischemia. However, vertebral artery stenting
VAS) has not received the detailed scientific study that has been
ccorded to carotid artery stenting (CAS).
In their series, Jenkins et al. (1) show excellent results. These
esults add to the growing body of nonrandomized studies that
emonstrate the feasibility and relative safety of VAS (2). Based on
heir outcomes, the authors recommend a more liberal use of VAS.
owever, several issues remain unresolved that beg for a more
autious approach.
No recent study of sufficient size has investigated the impact of
ptimal medical regimen on the natural history of VA disease or
ompared it with VAS (3). Further, there are several unresolved
ssues regarding optimal endovascular strategy. Bilateral VA ste-
osis presents a clinical challenge. Unlike anterior circulation
schemia, vertebrobasilar ischemia symptoms are difficult to later-
lize to one side. It is not known whether unilateral VAS will
esolve the symptoms or whether bilateral VAS is indicated. The
uthors report that 54.3% patients had bilateral VA disease,
lthough only 6.3% of the subjects received bilateral stents. It is
nclear how the stented side was chosen and whether symptoms
esolved completely.
Subclavian artery stenosis without coexistent VA stenosis can
ause vertebrobasilar ischemia (4). In the current study, 29.2% of
he subjects had concurrent subclavian artery disease. It will be
seful to know whether the subclavian artery was also stented
oncomitantly.
The present study did not use distal embolic protection,
lthough this is the standard in CAS. This is an important issue in
AS with only limited data available (5).
Another important issue is restenosis. Unlike CAS, which has a
ow risk of restenosis, VAS has a significantly higher restenosis rate
6,7). Little information is available regarding the use of drug-
luting stents, although initial reports indicate a lower restenosis
ate (8).
Jenkins et al. (1) demonstrate that VAS is relatively safe and
easible. However, before more widespread use, VAS should
ndergo the same meticulous investigation as CAS has been
ccorded. This will involve a direct comparison with optimal
edical therapy and use of current endovascular standards (distal
mbolic protection and perhaps drug-eluting stents).
